Safety and side effects of the insulin analogues

Bibliography

• ROSENFELD L: Insulin: discovery and controversy. Clin. Chem. (2002) 48(12):2270-2288.
   PubMed Web of Science ®Google Scholar
• BLISS M: The history of insulin. Diabetes Care (1993) 16(Suppl. 3):4-7.
   PubMedGoogle Scholar
• HIRSCH IB: Insulin analogues. N. Engl. J. Med. (2005) 352(2):174-183.
   PubMed Web of Science ®Google Scholar
• BRANGE J, OWENS DR, KANG S, VOLUND A: Monomeric insulins and their experimental and clinical implications. Diabetes Care (1990) 13(9):923-954.
   PubMed Web of Science ®Google Scholar
• BARNETT AH, OWENS DR: Insulin analogues. Lancet (1997) 349(9044):47-51.
   PubMed Web of Science ®Google Scholar
• ZINMAN B: The physiologic replacement of insulin. An elusive goal. N. Engl. J. Med. (1989) 321(6):363-370.
   PubMed Web of Science ®Google Scholar
• KANG S, BRANGE J, BURCH A, VOLUND A, OWENS DR: Subcutaneous insulin absorption explained by insulin’s physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care (1991) 14(11):942-948.
   PubMed Web of Science ®Google Scholar
• JORGENSEN LN, NIELSEN FS: Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen: a questionnaire study (abstract). Diabetologia (1990) 33:A116.
   Google Scholar
• BARNETT AH: A review of basal insulins. Diabet. Med. (2003) 20(11):873-885.
   PubMed Web of Science ®Google Scholar
• BINDER C, LAURITZEN T, FABER O, PRAMMING S: Insulin pharmacokinetics. Diabetes Care (1984) 7(2):188-199.
   PubMed Web of Science ®Google Scholar
• HEINEMANN L: Variability of insulin absorption and insulin action. Diabetes Technol. Ther. (2002) 4(5):673-682.
   PubMedGoogle Scholar
• NO AUTHORS LISTED: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. (1993) 329(14):977-986.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 352(9131):837-853.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes (1997) 46(2):271-286.
   PubMed Web of Science ®Google Scholar
• BOLLI GB, DI MARCHI RD, PARK GD, PRAMMING S, KOIVISTO VA: Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia (1999) 42(10):1151-1167.
   PubMed Web of Science ®Google Scholar
• BRANGE J: Design of insulin analogues for meal-related therapy. J. Diabetes Complications (1993) 7(2):106-112.
   PubMedGoogle Scholar
• HOLLEMAN F, HOEKSTRA JB: Insulin lispro. N. Engl. J. Med. (1997) 337(3):176-183.
   PubMed Web of Science ®Google Scholar
• SIMPSON KL, SPENCER CM: Insulin aspart. Drugs (1999) 57(5):759-765.
   PubMed Web of Science ®Google Scholar
• CAMPBELL RK, WHITE JR, LEVIEN T, BAKER D: Insulin glargine. Clin Ther. (2001) 23(12):1938-1957.
   PubMed Web of Science ®Google Scholar
• DEWITT DE, HIRSCH IB: Outpatient insulin therapy in Type 1 and Type 2 diabetes mellitus: scientific review. JAMA (2003) 289(17):2254-2264.
   PubMed Web of Science ®Google Scholar
• HEINEMANN L, SINHA K, HEISE T et al.: Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet. Med. (1999) 16(4):332-338.
   PubMed Web of Science ®Google Scholar
• HEINEMANN L, SEDLAK M, HEISE T: Time-action profile of the long- acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care (2000) 23:644-649.
   PubMed Web of Science ®Google Scholar
• LEESE GP, MORRISON W, FRIER BM; DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in Type 1 and Type 2 diabetes: a population-based study of health service resource use. Diabetes Care (2003) 26(4):1176-1180.
   PubMed Web of Science ®Google Scholar
• MACLEOD KM, HEPBURN DA, FRIER BM: Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet. Med. (1993) 10(3):238-245.
   PubMed Web of Science ®Google Scholar
• CRYER PE: Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab. Res. Rev. (1999) 15(1):42-46.
   PubMed Web of Science ®Google Scholar
• HOME PD, LINDHOLM A, HYLLEBERG B, ROUND P: Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in Type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care (1998) 21(11):1904-1909.
   PubMed Web of Science ®Google Scholar
• ANDERSON JH Jr, BRUNELLE RL, DIMARCHI R et al.: Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes (1997) 46(2):265-270.
   PubMed Web of Science ®Google Scholar
• HELLER SR, AMIEL SA, MANSELL P: Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care (1999) 22(10):1607-1611.
   PubMed Web of Science ®Google Scholar
• HELLER SR, COLAGIURI S, VAALER S et al.: Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabet. Med. (2004) 21(7):769-775.
   PubMed Web of Science ®Google Scholar
• BRUNELLE BL, LLEWELYN J, ANDERSON JH Jr, GALE EA, KOIVISTO VA: Meta – analysis of the effect of insulin lispro on severe hypoglycaemia in patients with Type 1 diabetes. Diabetes Care (1998) 21(10):1726-1731.
   PubMed Web of Science ®Google Scholar
• SIEBENHOFER A, PLANK J, PIEBER TR: Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst. Rev. (2004):CD003287.
   Google Scholar
• RATNER RE, HIRSCH IB, WILSON CA et al.: Less hypoglycemia with insulin glargine in intensive insulin therapy for Type 1 diabetes. US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care (2000) 23(5):639-643.
   PubMed Web of Science ®Google Scholar
• PIEBER TR, EUGENE-JOLCHINE I, DEROBERT E: Efficacy and safety of HOE 901 versus NPH insulin in patients with Type 1 diabetes. The European Study Group of HOE 901 in Type 1 diabetes. Diabetes Care (2000) 23(2):157-162.
   PubMed Web of Science ®Google Scholar
• RASKIN P, KLAFF L, BERGENSTAL R, HALLE JP, DONLEY D, MECCA T: A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with Type 1 diabetes. Diabetes Care (2000) 23(11):1666-1671.
   PubMed Web of Science ®Google Scholar
• ROSENSTOCK J, PARK G, ZIMMERMAN J: US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with Type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care (2002) 23(8):1137-1142.
   Web of Science ®Google Scholar
• HOME P, BARTLEY P, RUSSELL-JONES D, DRAEGER E et al.: Study To Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with Type 1 diabetes: a randomized clinical trial. Diabetes Care (2004) 27(5):1081-1087.
   PubMed Web of Science ®Google Scholar
• VAGUE P, SELAM JL, DRAEGER E et al.: Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with Type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care (2003) 26(3):590-596.
   PubMed Web of Science ®Google Scholar
• HEISE T, DRAEGER E: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with Type 1 diabetes. Diabetes (2004) 53(6):1614-1620.
   PubMed Web of Science ®Google Scholar
• ROBINSON RT, HARRIS ND, HELLER SR et al.: Mechanisms of abnormal cardiac repolarisation during insulin-induced hypoglycemia. Diabetes (2003) 52(6):1469-1474.
   PubMed Web of Science ®Google Scholar
• ROBINSON RT, HARRIS ND, IRELAND RH, LINDHOLM A, HELLER SR: Comparative effect of human soluble insulin and insulin aspart upon hypoglycaemia-induced alterations in cardiac repolarization. Br. J. Clin. Pharmacol. (2003) 55(3):246-251.
   PubMed Web of Science ®Google Scholar
• FRIER BM, EWING FM, LINDHOLM A, HYLLEBERG B, KANC K: Symptomatic and counterregulatory hormonal responses to acute hypoglycaemea induced by insulin aspart and soluble human insulin in Type 1 diabetes. Diabetes Metab. Res. Rev. (2000) 16(4):262-268.
   PubMed Web of Science ®Google Scholar
• KALAMBOKIS GN, TSATSOULIS AA, TSIANOS EV: The edematogenic properties of insulin. Am. J. Kidney Dis. (2004) 44(4):575-590.
   PubMed Web of Science ®Google Scholar
• PURNELL JQ, HOKANSON JE, BRUNZELL JD et al.: Effect of excessive weight gain with intensive therapy of Type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA (1998) 280(2):140-146.
   PubMed Web of Science ®Google Scholar
• DE LEEUW I, VAGUE P, ELTE JW et al.: Insulin detemir used in basal-bolus therapy in people with Type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes. Metab. (2005) 7(1):73-82.
   PubMed Web of Science ®Google Scholar
• HAAK T, TIENGO A, WALDHAUSL W et al.: Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with Type 2 diabetes. Diabetes Obes. Metab. (2005) 7(1):56-64.
   PubMed Web of Science ®Google Scholar
• CHANTELAU E, ECHTERHOFF S et al.: What makes insulin injections painful? Br. Med. J. (1991) 303(6793):26-27.
   PubMed Web of Science ®Google Scholar
• RATNER RE, PHILLIPS TM, STEINER M: Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates. Diabetes (1990) 39(6):728-733.
   PubMed Web of Science ®Google Scholar
• DESHAZO RD: Insulin allergy and insulin resistance: two immunologic reactions. Postgrad Med. (1978) 63(1):85-92.
   PubMed Web of Science ®Google Scholar
• MCNALLY PG, JOWETT NI, KURINCZUK JJ, PECK RW, HEARNSHAW JR: Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins. Postgrad. Med. J. (1988) 64(757):850-853.
   PubMed Web of Science ®Google Scholar
• SCHERNTHANER G: Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care (1993) 16(Suppl. 3):155-165
   PubMed Web of Science ®Google Scholar
• WITTERS LA, OHman JL, WEIR GC, RAYMOND LW, LOWELL FC: Insulin antibodies in the pathogenesis of insulin allergy and resistance. Am. J. Med. (1977) 63(5):703-709.
   PubMed Web of Science ®Google Scholar
• FINEBERG SE, HUANG J, BRUNELLE R, GULLIYA KS, ANDERSON JH Jr: Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with Type 1 or Type 2 diabetes. Diabetes Care (2003) 26(1):89-96.
   PubMed Web of Science ®Google Scholar
• FINEBERG SE, GALLOWAY JA, FINEBERG NS, GOLDMAN J: Effects of species of origin, purification levels, and formulation on insulin immunogenicity. Diabetes (1983) 32(7):592-599.
   PubMed Web of Science ®Google Scholar
• REEVES WG, ALLEN BR, TATTERSALL RB: Insulin-induced lipoatrophy: evidence for an immune pathogenesis. Br. Med. J. (1980) 280(6230):1500-1503.
   PubMed Web of Science ®Google Scholar
• ATLAN-GEPNER C, BONGRAND P, VIALETTES B et al.: Insulin-induced lipoatrophy in Type I diabetes. A possible tumor necrosis factor-alpha-mediated dedifferentiation of adipocytes. Diabetes Care (1996) 19(11):1283-1285.
   PubMed Web of Science ®Google Scholar
• GRIFFIN ME, FEDER A, TAMBORLANE WV: Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause? Diabetes Care (2001) 24(1):174.
   PubMed Web of Science ®Google Scholar
• AMPUDIA-BLASCO FJ, HASBUM B, CARMENA R: A new case of lipoatrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications? Diabetes Care (2003) 26(3):953-954.
   PubMed Web of Science ®Google Scholar
• ARRANZ A, ANDIA V, LOPEZ-GUZMAN A: A case of lipoatrophy with Lispro insulin without insulin pump therapy [case reports letter]. Diabetes Care (2000) 27(2):625-626.
   Web of Science ®Google Scholar
• SOLA-GAZAGNES A, PECQUET C, SELAM JL: Successful treatment of insulin allergy in a Type 1 diabetic patient by means of constant subcutaneous pump infusion of insulin. Diabetes Care (2003) 26(10):2961-2962.
   PubMed Web of Science ®Google Scholar
• LAHTELA JT, KNIP M, PAUL R, ANTONEN J, SALMI J: Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. A case report. Diabetes Care (1997) 20(1):71-73.
   PubMed Web of Science ®Google Scholar
• KUMAR D: Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care (1997) 20(9):1357-1359.
   PubMed Web of Science ®Google Scholar
• ABRAHAM MR, Al-SHARAFI BA, SAAVEDRA GA, KHARDORI R: Lispro in the treatment of insulin allergy [case reports letter]. Diabetes Care (1999) 22(11):1916-1917.
   PubMed Web of Science ®Google Scholar
• AIRAGHI L, LORINI M, TEDESCHI A: The insulin analog aspart: a safe alternative in insulin allergy. Diabetes Care (2001) 24(11):2000.
   PubMed Web of Science ®Google Scholar
• YASUDA H, NAGATA M, YOKONO K et al.: Human insulin analog insulin aspart does not cause insulin allergy. Diabetes Care (2001) 24(11):2008-2009
   PubMed Web of Science ®Google Scholar
• TAKATA H, KUMON Y, HASHIMOTO K et al.: The human insulin analogue aspart is not the almighty solution for insulin allergy. Diabetes Care (2003) 26(1):253-254.
   PubMed Web of Science ®Google Scholar
• DURAND-GONZALEZ KN, GUILLAUSSEAU N, PECQUET C, GAYNO JP: Glargine insulin is not an alternative in insulin allergy. Diabetes Care (2003) 26(7):2216.
   PubMed Web of Science ®Google Scholar
• DIXON AN, BAIN SC: Nausea and vomiting due to insulin glargine in patient with Type 1 diabetes mellitus. Br. Med. J. (2005) 330(7489):455.
   PubMed Web of Science ®Google Scholar
• MORIYAMA H, NAGATA M, YOKONO K et al.: Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in Type 1 diabetes. Diabetes Care (2001) 24(2):411-412.
   PubMed Web of Science ®Google Scholar
• COMBS CA, GUNDERSON E, MAIN EK et al.: Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care (1992) 15(10):1251-1257.
   PubMed Web of Science ®Google Scholar
• DE VECIANA M, MAJOR CA, EVANS AT et al.: Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N. Engl. J. Med. (1995) 333(19):1237-1241.
   PubMed Web of Science ®Google Scholar
• JOVANOVIC L, ILIC S, PETTITT DJ et al.: Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care (1999) 22(9):1422-1427.
   PubMed Web of Science ®Google Scholar
• MENON RK, COHEN RM, SPERLING MA, CUTFIELD WS, MIMOUNI F, KHOURY JC: Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus. Its role in fetal macrosomia. N. Engl. J. Med. (1990) 323(5):309-315.
   PubMed Web of Science ®Google Scholar
• DIAMOND T, KORMAS N: Possible adverse fetal effect of insulin lispro. N. Engl. J Med. (1997) 337(14):1009.
   PubMed Web of Science ®Google Scholar
• KITZMILLER JL, BUCHANAN TA, RATNER RE et al.: Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Diabetes Care (1996) 19(5):514-541.
   PubMed Web of Science ®Google Scholar
• WYATT JW, FRIAS JL, HOYME HE et al.: IONS study group. Lilly Research Laboratories. Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet. Med. (2005) 22(6):803-807.
   PubMed Web of Science ®Google Scholar
• KITZMILLER JL, MAIN E, WARD B, THEISS T, PETERSON DL: Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care (1999) 22(5):874-876.
   PubMed Web of Science ®Google Scholar
• CHEW EY, MILLS JL, JOVANOVIC-PETERSON L et al.: Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care (1995) 18(5):631-637.
   PubMed Web of Science ®Google Scholar
• LACHIN J, CLEARLY P AND THE DCCT RESEARCH GROUP: Pregnancy increases the risk of complication in the DCCT. Diabetes (1998) 47(Suppl. 1):1091.
   Google Scholar
• DI CIANNI G, VOLPE L, LENCIONI C et al.: Use of insulin glargine during the first weeks of pregnancy in five Type 1 diabetic women. Diabetes Care (2005) 28:982-983.
   PubMed Web of Science ®Google Scholar
• FORD-ADAMS ME, MURPHY MP, MOORE EJ et al.: Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet. Med. (2003) 20(8):656-660.
   PubMed Web of Science ®Google Scholar
• CHASE HP, DIXON B, PEARSON J et al.: Reduced hypoglycemic episodes and improved glycemic control in children with Type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J. Pediatr. (2003) 143(6):737-740.
   PubMed Web of Science ®Google Scholar
• COLINO E, ALONSO M, BARRIO R et al.: Therapy with insulin glargine in toddlers, children and adolescents with Type 1 diabetes. Diabetes Res. Clin. Pract. (2005) 70(1):1-7.
   PubMed Web of Science ®Google Scholar
• DIXON B, CHASE HP, BURDICK J et al.: Use of insulin glargine in children under age 6 with Type 1 diabetes. Pediatric Diabetes (2005) 6(3):150-154
   PubMed Web of Science ®Google Scholar
• DANNE T, LUPKE K, WALTE K, VON SCHUETZ W, GALL MA et al.: Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with Type 1 diabetes. Diabetes Care (2003) 26(11):3087-3092.
   PubMed Web of Science ®Google Scholar
• SLIEKER LJ, BROOKE GS, CHANCE RE et al.: Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia (1997) 40(Suppl. 2):S54-S61.
   PubMed Web of Science ®Google Scholar
• HANSEN BF, KLEIN HH, LUNDEMOSE AG et al.: Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem. J. (1996) 315(Pt 1):271-279.
   PubMed Web of Science ®Google Scholar
• KURTZHAL P, SCHAFFER L, TRUB T et al.: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes (2000) 49(6):999-1005.
   PubMed Web of Science ®Google Scholar
• CIARALDI TP, CARTER L, SEIPKE G, MUDALIAR S, HENRY RR: Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J. Clin. Endocrinol. Metab. (2001) 86(12):5838-5847.
   PubMed Web of Science ®Google Scholar
• HOFMANN T, HORSTMANN G, STAMMBERGER I: Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int. J. Toxicol. (2002) 21(3):181-189.
   PubMed Web of Science ®Google Scholar
• BERTI L, KELLERER M, HARING HU et al.: The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm. Metab. Res. (1998) 30(3):123-129.
   PubMed Web of Science ®Google Scholar
• WEISSBERG-BENCHELL J, ANTISDEL-LOMAGLIO, SESHADRI R: Insulin pump therapy: a meta-analysis. Diabetes Care (2003) 26(4):1079-1087.
   PubMed Web of Science ®Google Scholar
• POULSEN C, LANGKJÆR L, WORSØE C: Precipitation of insulin products used for continuous subcutaneous insulin infusion. Diabetes Technol. Ther. (2005) 7(1):142-150.
   PubMedGoogle Scholar
• WOLPERT HA, FARADJI RN, BONNER-WEIR S, LIPES MA: Metabolic decompensation in pump users due to lispro insulin precipitation. Br. Med. J. (2002) 324(7348):1253.
   PubMed Web of Science ®Google Scholar
• ZINMAN B, TILDESLEY H, CHIASSON JL, TSUI E, STRACK T: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes (1997) 46(3):440-443.
   PubMed Web of Science ®Google Scholar